LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | uM | LJP5 | 3 | N24 | 72 | hr | 1209 | 4212 | 4376 | 0.9625 | 0.9592 | ||
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 1 | A18 | 72 | hr | 1401 | 1374 | 3978 | 0.3454 | -0.0131 |
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 2 | A18 | 72 | hr | 1401 | 1725 | 4213 | 0.4094 | 0.1397 |
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 3 | A18 | 72 | hr | 1401 | 1515 | 4545 | 0.3333 | 0.0469 |
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 1 | A17 | 72 | hr | 1401 | 1416 | 3978 | 0.3559 | 0.0068 |
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 2 | A17 | 72 | hr | 1401 | 1574 | 4213 | 0.3736 | 0.0758 |
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 3 | A17 | 72 | hr | 1401 | 1544 | 4545 | 0.3396 | 0.0587 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 1 | A16 | 72 | hr | 1401 | 1455 | 3978 | 0.3657 | 0.0252 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 2 | A16 | 72 | hr | 1401 | 1327 | 4213 | 0.3150 | -0.0338 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 3 | A16 | 72 | hr | 1401 | 1443 | 4545 | 0.3174 | 0.0173 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 1 | A15 | 72 | hr | 1401 | 1400 | 3978 | 0.3519 | -0.0007 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 2 | A15 | 72 | hr | 1401 | 1635 | 4213 | 0.3881 | 0.1019 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 3 | A15 | 72 | hr | 1401 | 1410 | 4545 | 0.3102 | 0.0036 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 1401 | 1413 | 3978 | 0.3552 | 0.0054 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 2 | A14 | 72 | hr | 1401 | 1549 | 4213 | 0.3677 | 0.0650 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 1401 | 1285 | 4545 | 0.2827 | -0.0498 |
| SK-BR-3 | Neratinib | 10 | uM | LJP5 | 1 | A13 | 72 | hr | 1401 | 1177 | 3978 | 0.2958 | -0.1095 |
| SK-BR-3 | Neratinib | 10 | uM | LJP5 | 2 | A13 | 72 | hr | 1401 | 1513 | 4213 | 0.3591 | 0.0494 |
| SK-BR-3 | Neratinib | 10 | uM | LJP5 | 3 | A13 | 72 | hr | 1401 | 1344 | 4545 | 0.2957 | -0.0244 |
| MDA-MB-231 | Neratinib | 0.04 | uM | LJP5 | 1 | A18 | 72 | hr | 1235 | 4638 | 4474 | 1.0365 | 1.0390 |
| MDA-MB-231 | Neratinib | 0.04 | uM | LJP5 | 2 | A18 | 72 | hr | 1235 | 4730 | 4578 | 1.0331 | 1.0347 |
| MDA-MB-231 | Neratinib | 0.04 | uM | LJP5 | 3 | A18 | 72 | hr | 1235 | 4733 | 4929 | 0.9602 | 0.9597 |
| MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 1 | A17 | 72 | hr | 1235 | 4650 | 4474 | 1.0392 | 1.0418 |
| MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 2 | A17 | 72 | hr | 1235 | 4451 | 4578 | 0.9721 | 0.9703 |
| MDA-MB-231 | Neratinib | 0.12 | uM | LJP5 | 3 | A17 | 72 | hr | 1235 | 4494 | 4929 | 0.9117 | 0.9095 |